Last updated: September 16, 2026
Belinostat, marketed in the United States as Beleodaq, is an intravenous histone deacetylase inhibitor approved for relapsed or refractory peripheral T-cell lymphoma (PTCL). Its commercial profile is constrained by a narrow indication, hospital-based administration, competition from other lymphoma therapies, and the end of U.S. orphan-drug exclusivity in 2021. Acrotech Biopharma owns and markets the product in the United States following its acquisition of Spectrum Pharmaceuticals.
Public information supports a mature, niche oncology product rather than a high-growth asset. Spectrum reported rising Beleodaq sales before its 2019 acquisition, but Acrotech does not publicly disclose standalone product revenue. Generic competition is possible after applicable patent barriers expire, although the product’s small market and injectable presentation may limit commercial entry.
What is belinostat and what is Beleodaq approved to treat?
Belinostat is a selective histone deacetylase inhibitor administered by intravenous infusion. The FDA approved Beleodaq on July 3, 2014, under the accelerated-approval pathway for adults with relapsed or refractory PTCL after prior therapy [1].
The approved indication is based on the response rate observed in the BELIEF clinical trial. The FDA label reported an overall response rate of 25.8%, including complete and partial responses, among 120 evaluable patients [2].
| Product |
Active ingredient |
Dosage form |
FDA indication |
U.S. sponsor |
| Beleodaq |
Belinostat |
Intravenous injection after dilution |
Relapsed or refractory PTCL |
Acrotech Biopharma |
| Folotyn |
Pralatrexate |
Intravenous injection |
Relapsed or refractory PTCL |
Acrotech Biopharma |
| Istodax |
Romidepsin |
Intravenous infusion |
Historically PTCL and other hematologic malignancies |
Bristol Myers Squibb, formerly Celgene |
Belinostat is used primarily after prior systemic treatment. It is not a broad first-line lymphoma product, which limits patient volume and reduces its exposure to large community-oncology markets.
When does belinostat lose exclusivity?
Belinostat’s FDA orphan-drug exclusivity expired in July 2021. Orphan exclusivity prevents FDA approval of the same drug for the same indication for seven years, subject to statutory exceptions. It is separate from patent protection and does not prevent patents from continuing after the orphan period ends.
The commercial exclusivity timeline is:
| Event |
Date or status |
| U.S. approval |
July 3, 2014 |
| Orphan-drug exclusivity |
Expired in July 2021 |
| Accelerated-approval basis |
BELIEF response-rate data |
| Confirmatory obligation |
Required under accelerated approval |
| Current commercial owner |
Acrotech Biopharma |
| Generic competition |
No broadly reported commercial generic launch identified in the public record through mid-2024 |
The end of orphan exclusivity opened the regulatory pathway for competing applications. It did not automatically create immediate generic competition because an applicant still must satisfy FDA requirements and address any unexpired patents, regulatory exclusivity, manufacturing complexity, and market economics.
What patents protect belinostat?
Belinostat’s patent estate includes composition-of-matter and related intellectual-property rights originating with TopoTarget, the company that developed the molecule before Spectrum acquired U.S. commercialization rights.
The principal publicly associated U.S. patent is U.S. Patent No. 8,546,599, which covers belinostat-related hydroxamic-acid compounds. Patent databases commonly associate this patent with belinostat, but the enforceable expiration date depends on patent-term adjustment, terminal disclaimers, and the exact claim scope relevant to a competing product.
A precise current patent-risk assessment must distinguish among:
- Active-ingredient claims covering belinostat or related compounds.
- Pharmaceutical-composition claims.
- Formulation and stability claims.
- Manufacturing-process claims.
- Method-of-use claims for PTCL or other malignancies.
- FDA Orange Book listings and their current expiration dates.
The FDA Orange Book, rather than commercial patent databases alone, is the controlling public source for patents listed against an approved small-molecule product. Belinostat’s commercial risk cannot be assessed solely from the expiration of the original molecule patent.
What formulations are protected by belinostat patents?
The marketed product is a sterile injectable formulation that requires reconstitution and dilution before intravenous administration. Formulation and manufacturing claims can be commercially relevant because injectable oncology products require validated sterility, container-closure compatibility, stability, and release testing.
These barriers are meaningful but usually weaker than composition-of-matter protection. A generic applicant can attempt to design around formulation claims while matching the reference product’s active ingredient, route, strength, and quality attributes.
Are method-of-use patents important for Beleodaq?
Method-of-use protection may cover treatment of PTCL or other hematologic cancers with belinostat. Such claims can affect the labeling strategy of an abbreviated new drug application, particularly where the patented use is included in the reference product’s labeling.
The practical value of method-of-use patents is narrower than composition patents. A generic applicant may pursue a section viii statement or a label carve-out for a patented indication if the remaining label supports a lawful non-infringing use.
What is the FDA regulatory status of belinostat?
Beleodaq remains an FDA-approved product for relapsed or refractory PTCL. Its approval was accelerated, meaning the FDA relied on a surrogate or intermediate endpoint and required post-approval evidence.
The regulatory profile has three commercial implications:
- The indication is established in the U.S. label.
- The product has a narrower evidence base than a drug approved through a large confirmatory survival or progression-free-survival program.
- Failure or delay of confirmatory obligations could create regulatory risk, including labeling restrictions or withdrawal proceedings.
The FDA’s accelerated-approval framework requires postmarketing studies to verify clinical benefit. Public drug labeling and FDA oncology materials should be monitored for changes to confirmatory-study status and indication language [1, 2].
What was the financial trajectory of Beleodaq?
Beleodaq generated increasing revenue during Spectrum Pharmaceuticals’ commercialization period. Spectrum’s filings described product sales growth as the company expanded commercialization of Beleodaq and its other oncology assets.
The main financial pattern was:
| Period |
Financial trajectory |
| 2014-2015 |
Early launch and market-access buildout |
| 2016-2018 |
Commercial growth from a small PTCL base |
| 2019 |
Spectrum acquired by Aurobindo’s Acrotech Biopharma |
| 2020 onward |
Product held by a private operating company with limited standalone disclosure |
| 2021 onward |
Orphan exclusivity ended, increasing long-term generic risk |
Spectrum’s public filings reported Beleodaq product sales in the tens of millions of dollars annually before the acquisition. The product was commercially important to Spectrum but remained a niche asset relative to large oncology products. After the Acrotech transaction, standalone Beleodaq sales, gross margin, promotional spending, and cash contribution were no longer disclosed in the same level of detail in public-company filings.
This limits precise valuation of the asset. The strongest observable financial indicators are the historical sales trend, the size of the PTCL treatment population, the product’s price per treatment course, and the duration of generic-free commercialization.
How does belinostat compare with competing PTCL drugs?
Belinostat competes mainly with other therapies used after prior treatment. Competition is based on response rate, tolerability, administration burden, physician familiarity, payer coverage, and the availability of clinical-trial options.
| Drug |
Mechanism |
Administration |
Commercial position |
| Beleodaq |
HDAC inhibitor |
Intravenous infusion |
Approved for relapsed or refractory PTCL |
| Istodax |
HDAC inhibitor |
Intravenous infusion |
Competing HDAC inhibitor; historical PTCL use |
| Folotyn |
Antifolate |
Intravenous injection |
Direct PTCL competitor |
| Monjuvi |
CD19-directed immunotherapy |
Intravenous infusion |
More concentrated in B-cell lymphoma, not a direct substitute for all PTCL patients |
| Romidepsin combinations |
HDAC inhibitor-based regimens |
Intravenous |
Clinical-use competition where combination therapy is favored |
Folotyn is particularly relevant because Acrotech markets both Folotyn and Beleodaq. The shared commercial owner can coordinate sales coverage, but the products also compete for treatment decisions within the same limited PTCL market.
Istodax’s U.S. PTCL indication was voluntarily withdrawn after confirmatory-study developments, reducing direct labeled competition among HDAC inhibitors. That withdrawal did not eliminate off-label use or competition from other systemic therapies.
Which companies are challenging belinostat?
No major publicly documented Paragraph IV litigation campaign against Beleodaq has become a defining feature of the product’s commercial history through mid-2024. The absence of visible litigation does not establish that no abbreviated application has been filed. Generic applicants can submit patent certifications without immediately producing a public dispute, and litigation may depend on whether the reference sponsor files suit within the statutory period.
The main potential challengers would be generic injectable-drug manufacturers with sterile oncology manufacturing capacity. Likely commercial constraints include:
- Small addressable patient population.
- Need for oncology-provider and hospital distribution.
- Sterile manufacturing requirements.
- Limited revenue opportunity after price erosion.
- Potential patent and labeling disputes.
- Competition from established alternative therapies.
What generic entry risks exist for belinostat?
Generic entry risk is moderate over the long term and lower in the immediate term when measured by commercial attractiveness.
A generic belinostat applicant could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the injectable product. The applicant would need to address:
- Active ingredient identity and strength.
- Sterility and particulate control.
- Reconstitution and dilution instructions.
- Stability and container-closure performance.
- Patent certifications.
- Labeling differences for any protected method of use.
The first generic entrant could obtain meaningful price share if the reference product has no active competing generic. Later entrants would likely cause sharper price erosion. Because the market is narrow, one or two entrants could materially reduce branded revenue.
A 30-month stay could arise if the sponsor files patent litigation after receiving a Paragraph IV notice. Its commercial effect depends on the patents asserted and whether those patents cover the active ingredient, formulation, or only a narrower use.
Is belinostat exposed to biosimilar risk?
Belinostat has no biosimilar risk because it is a chemically synthesized small molecule, not a biologic. The relevant challenge pathway is an ANDA or, depending on the product and formulation, another small-molecule regulatory route.
The key substitution risk is therefore generic competition, not biosimilar interchangeability. Pharmacy substitution rules and hospital purchasing agreements will be more relevant than biologic interchangeability standards.
What licensing deals affect belinostat?
TopoTarget licensed U.S. commercialization rights for belinostat to Spectrum Pharmaceuticals. Spectrum launched Beleodaq after FDA approval. Aurobindo Pharmaceuticals later acquired Spectrum, and Acrotech Biopharma became the commercial owner of Spectrum’s oncology portfolio, including Beleodaq.
The transaction chain is:
| Period |
Rights holder or commercial participant |
| Development period |
TopoTarget |
| U.S. commercialization |
Spectrum Pharmaceuticals |
| 2019 acquisition |
Aurobindo Pharma acquired Spectrum |
| Current U.S. commercialization |
Acrotech Biopharma |
The deal structure matters because current economic ownership may include royalties, milestone obligations, or territorial rights that are not fully visible in current product-level disclosures. The public record supports the transfer of commercialization control but does not provide a current standalone royalty model for Beleodaq.
How strong is the belinostat patent estate?
The estate is commercially meaningful but no longer supported by orphan exclusivity. Its strength depends on whether enforceable claims remain directed to the active ingredient or whether protection is limited to formulation, manufacturing, or specific uses.
The strength assessment is:
| Factor |
Assessment |
| Active ingredient |
Historically important composition protection |
| Orphan exclusivity |
Expired |
| Formulation protection |
Potentially relevant to injectable competition |
| Method-of-use protection |
Relevant to label strategy and litigation |
| Manufacturing barriers |
Meaningful for sterile injectable products |
| Market size |
Limits expected generic returns |
| Litigation record |
No defining public Paragraph IV campaign identified through mid-2024 |
| Overall position |
Mature niche product with declining exclusivity leverage |
The product’s manufacturing complexity may delay entry even after legal exclusivity weakens. It is not a substitute for patent protection, but it can reduce the number of economically viable competitors.
What is the likely market trajectory for belinostat?
Belinostat’s base-case trajectory is stable or declining U.S. revenue, with limited upside from price increases or incremental use in relapsed PTCL. Growth would require label expansion, combination-regimen adoption, or broader international commercialization.
The principal downside factors are:
- Expired orphan exclusivity.
- Potential ANDA filings.
- Hospital and payer pressure.
- Competing therapies for relapsed PTCL.
- Absence of a broad first-line indication.
- Limited disclosure of post-acquisition commercial investment.
Potential support for revenue includes:
- Physician familiarity.
- Established FDA approval.
- Use in a rare disease with limited treatment options.
- Injectable supply and distribution infrastructure.
- Possible continued value before generic entry.
No public evidence supports a high-growth forecast absent a new indication or clinically differentiated combination regimen.
Key Takeaways
- Belinostat is marketed as Beleodaq for relapsed or refractory PTCL.
- FDA approval occurred on July 3, 2014, under the accelerated-approval pathway.
- U.S. orphan-drug exclusivity expired in July 2021.
- Spectrum Pharmaceuticals commercialized the product before Aurobindo acquired Spectrum and transferred the asset to Acrotech Biopharma.
- Historical sales reached the tens of millions of dollars annually, but Acrotech does not publicly disclose current standalone Beleodaq revenue.
- Generic risk is the central long-term commercial threat. Biosimilar risk does not apply.
- The injectable formulation and sterile-manufacturing requirements create operational barriers but do not replace patent protection.
- The product is a mature niche oncology asset with limited growth visibility absent a new indication or combination strategy.
Frequently Asked Questions
Is belinostat still FDA approved?
Yes. Beleodaq remains FDA approved for adults with relapsed or refractory PTCL after prior therapy.
Is Beleodaq the same drug as belinostat?
Yes. Beleodaq is the U.S. brand name for the active ingredient belinostat.
Who manufactures Beleodaq?
Acrotech Biopharma is the U.S. commercial owner and sponsor associated with Beleodaq following Aurobindo’s acquisition of Spectrum Pharmaceuticals.
Can a generic company launch belinostat now?
A generic company may pursue FDA approval, but launch timing depends on ANDA approval, patent certifications, litigation, regulatory requirements, and sterile injectable manufacturing capacity.
Does belinostat have a future in combination therapy?
Potentially, but a commercially material combination opportunity would require supportive clinical evidence, physician adoption, reimbursement, and likely a regulatory or label-development strategy.
References
- U.S. Food and Drug Administration. (2014). FDA approves Beleodaq for treatment of peripheral T-cell lymphoma. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). Beleodaq (belinostat) prescribing information. Acrotech Biopharma.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- Spectrum Pharmaceuticals, Inc. (2018). Form 10-K annual report. U.S. Securities and Exchange Commission.
- Aurobindo Pharma Limited. (2019). Aurobindo Pharma completes acquisition of Spectrum Pharmaceuticals. Company release.
- National Cancer Institute. (2024). Peripheral T-cell lymphoma treatment information. https://www.cancer.gov
- U.S. Patent No. 8,546,599. (2013). Hydroxamic acid derivatives and uses thereof. U.S. Patent and Trademark Office.
